David Deniaud

Title: David Deniaud: A Pioneer in Gene Therapy Innovations

Introduction

David Deniaud is an accomplished inventor located in Nantes, France. He has made significant contributions to the field of gene therapy, evidenced by his four patents. Deniaud’s innovative work primarily focuses on the development of recombinant Adeno-Associated Virus (rAAV) vector particles for effective gene delivery.

Latest Patents

Among Deniaud's most notable inventions is the patent for the rAAV with chemically modified capsid. This invention involves a recombinant Adeno-Associated Virus vector particle that contains at least one primary amino group in its capsid proteins. The invention details a method for chemically coupling a ligand to the capsid, utilizing a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. This groundbreaking method has implications for gene therapy, facilitating targeted delivery to cells, tissues, and organs through viral vectors. Notably, the invention demonstrates the potential to modulate ligand coupling on the AAV surface, specifically examining the chemical coupling of mannose ligands for subretinal injection in rats. The pharmaceutical applications of this invention are vast, as it includes methods for producing rAAV vector particles and pharmaceutical compositions comprising these vectors for medical use.

Career Highlights

David Deniaud has worked with esteemed research institutions such as the Centre National de la Recherche Scientifique (CNRS) and the Institut National de la Santé et de la Recherche Médicale (INSERM). His tenure at these organizations further solidified his expertise and paved the way for his innovative endeavors in gene therapy.

Collaborations

Throughout his career, Deniaud has collaborated with other talented researchers, including Mathieu Mevel and Eduard Ayuso. Such collaborations have enhanced his research capabilities and the impact of his innovations in the scientific community.

Conclusion

David Deniaud stands out as a significant figure in the realm of gene therapy, driven by his passion for innovation and discovery. With his latest patents, he continues to pave the way for advancements in medical treatments, showcasing the potential of rAAV vector particles in gene delivery systems. His contributions will undoubtedly play a crucial role in shaping the future of gene therapy.